Clinical Trials
4 trialsNCT06710288 2025-10-20
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
ImmunityBio, Inc.
Phase 2 Recruiting
NCT04374630 2025-09-10
PROFECTA-II
Laekna Limited
Phase 2 Completed
NCT05736952 2023-05-11
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Withdrawn
NCT04376073 2020-11-25
ANNIE
Sun Yat-sen University
Phase 2 Unknown